Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | ACACB | O00763 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13744711 | 1.00 | TSHR (0.46) | TSHRACACBHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL23480156 | 0.83 | MMP1 (0.50) | TSHRACACBHPGDSMN1; SMN2THRB | |
| SCHEMBL67777 | 0.81 | TSHR (0.44) | TSHRACACBHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL67778 | 0.81 | TSHR (0.44) | TSHRACACBHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL13744321 | 0.80 | TSHR (0.47) | TSHRACACBHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL1036877 | 0.79 | — | — | |
| SCHEMBL4342682 | 0.79 | CNR2 (0.44) | ALDH1A1KCNK3THRBCNR2BLM | |
| SCHEMBL29334716 | 0.78 | TSHR (0.42) | TSHRACACBHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL8681480 | 0.77 | CNR2 (0.51) | ALDH1A1KCNK3THRBCNR2BLM | |
| SCHEMBL14948951 | 0.76 | TSHR (0.41) | TSHRACACBHPGDSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-7531537-B2 | Benzofuran derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209511-A1 | Benzofuran Derivatives | F12, F2, F3 | TSHR 2452/4885ACACB 2151/4885HPGD 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.